التفاصيل البيبلوغرافية
| العنوان: |
Quick efficacy seeking trial (QuEST1): a novel combination immunotherapy study designed for rapid clinical signal assessment metastatic castration-resistant prostate cancer. |
| المؤلفون: |
Redman, Jason M.1 Jason.Redman@nih.gov, Steinberg, Seth M.2,3, Gulley, James L.1 gulleyj@mail.nih.gov |
| المصدر: |
Journal for ImmunoTherapy of Cancer. 9/18/2018, Vol. 6 Issue 1, pN.PAG-N.PAG. 1p. |
| مصطلحات موضوعية: |
*CASTRATION-resistant prostate cancer, *IMMUNOTHERAPY |
| مستخلص: |
Advances in immunotherapy utilizing immune checkpoint inhibitors (ICIs) have transformed the treatment landscapes of several malignancies in recent years. Oncologists are now tasked with extending these benefits to a greater number of patients and tumor types. Metastatic castration-resistant prostate cancer (mCRPC) infrequently responds to ICIs, while the cellular vaccine approved for mCRPC, sipuleucel-T, provides a 4-month survival benefit but does not produce clinical responses as monotherapy. However, many novel and generally well-tolerated immune oncology agents with potential for immune synergy and/or additive effects are undergoing clinical development. This availability presents opportunities to develop adaptive-design combination clinical trials aimed to generate, expand, and facilitate antitumor immune responses. Here we describe a currently accruing phase I/II trial (NCT03493945) testing a brachyury-targeted antitumor vaccine, TGF-β TRAP/anti-PD-L1 antibody, an IL-15 agonist, and an IDO1 inhibitor in mCRPC. Trial registration: This trial (NCT03493945) was registered in National Clinical Trials on April 11th 2018. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: |
Academic Search Index |
Full Text Finder